Geron | GERN - Current Liabilities


Geron reported $64.28M in Current Liabilities for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 555.2M
Cash and Equivalent USD 79.6M
Cost of Sales USD 1.19M
Current Assets USD 505.6M
Current Liabilities USD 64.28M
Debt USD 121.84M
EBIT USD -12.45M
EBITDA USD -7.55M
Employees 229
EPS Earnings Per Share USD -0.02
Equity Capital and Reserves USD 259.53M
Gross Profit on Sales USD 47.85M
Interest Expense on Debt USD 8.52M
Interest Income USD 4.66M
Loan Capital USD 118.99M
Market Capitalization USD 846.3M
Net Income USD -16.38M
Operating Expenses USD 61.49M
Operating Profit USD -12.45M
Ordinary Share Capital USD 636.92M
Pre-Tax Profit USD -16.38M
Sales Revenues USD 49M
Selling and Administration Expenses USD 38.56M
Stock USD 69.13M
Trade Creditors USD 8.23M
Trade Debtors USD 39.36M

Current Liabilities Change Date
Amgen USD 20.48B 2.53B Jun/2025
Bio Techne USD 175.85M 6.64M Jun/2025
Cassava Sciences USD 47.33M 35.58M Jun/2025
Cytokinetics USD 131.06M 28.66M Jun/2025
Exelixis USD 336.11M 62.99M Jul/2025
Genmab DKK 629M 127M Jun/2025
Geron USD 64.28M 1.25M Jun/2025
Gilead Sciences USD 11.19B 1.15B Jun/2025
Incyte USD 1.28B 608.18M Jun/2025
MacroGenics USD 39M 16.53M Jun/2025
Novartis USD 31.71B 95M Jun/2025